Atlantic Union Bankshares Corp Has $816,000 Position in Novo Nordisk A/S $NVO

Atlantic Union Bankshares Corp increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 421.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,699 shares of the company’s stock after buying an additional 11,881 shares during the quarter. Atlantic Union Bankshares Corp’s holdings in Novo Nordisk A/S were worth $816,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Money Concepts Capital Corp raised its holdings in Novo Nordisk A/S by 5.0% in the 3rd quarter. Money Concepts Capital Corp now owns 58,564 shares of the company’s stock valued at $3,250,000 after acquiring an additional 2,781 shares in the last quarter. Guerra Advisors Inc bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $25,000. Strategy Asset Managers LLC raised its stake in shares of Novo Nordisk A/S by 6.9% in the third quarter. Strategy Asset Managers LLC now owns 4,364 shares of the company’s stock valued at $242,000 after purchasing an additional 280 shares in the last quarter. Jones Financial Companies Lllp raised its stake in shares of Novo Nordisk A/S by 10.3% in the third quarter. Jones Financial Companies Lllp now owns 149,885 shares of the company’s stock valued at $8,335,000 after purchasing an additional 14,017 shares in the last quarter. Finally, Arjuna Capital lifted its position in Novo Nordisk A/S by 3.5% in the third quarter. Arjuna Capital now owns 35,652 shares of the company’s stock worth $1,978,000 after purchasing an additional 1,209 shares during the period. 11.54% of the stock is currently owned by institutional investors.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Q4 beat on both EPS and revenue, showing underlying demand and margin resilience for 2025. Q4 earnings and slide deck
• Positive Sentiment: Pipeline wins: late-stage CagriSema diabetes data looked strong versus semaglutide, supporting longer-term growth potential beyond semaglutide products. CagriSema Phase III results
• Positive Sentiment: Product expansion: Novo plans a U.S. launch of an oral semaglutide (Ozempic pill) in Q2 2026, broadening access and addressing oral demand. Ozempic pill launch
• Neutral Sentiment: Capital return: Novo initiated a 2026 buyback programme (up to DKK 15bn, with a DKK 3.8bn tranche immediately), which supports shares but is also defensive. Share repurchase announcement
• Negative Sentiment: Guidance shock: management warned 2026 sales and operating profit will likely fall 5–13% (constant currency), the primary catalyst for the sell-off. 2026 outlook release
• Negative Sentiment: U.S. pricing pressure: management described “painful” Wegovy price cuts and deeper discounting that will compress margins this year. U.S. price cuts commentary
• Negative Sentiment: Competitive & execution risks: Eli Lilly’s strong guidance, manufacturing scale and cheaper oral competitors (and Pfizer data) raise the risk Novo can’t recover volumes/prices quickly; slower capacity ramp exacerbates the issue. MarketBeat: Metabolic split
• Negative Sentiment: Margin squeeze & cannibalization: analysts warn oral Wegovy may reduce higher‑margin injectable sales and raise production costs, worsening FY2026 profitability. Seeking Alpha on margin pressure

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $47.18 on Thursday. The stock has a market capitalization of $210.66 billion, a price-to-earnings ratio of 13.72 and a beta of 0.67. The firm’s 50-day moving average price is $53.75 and its two-hundred day moving average price is $54.13. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 4th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NVO has been the topic of several analyst reports. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 29th. BMO Capital Markets set a $57.00 price target on shares of Novo Nordisk A/S in a research note on Monday, January 26th. TD Cowen reiterated a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday. Finally, Hsbc Global Res cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $57.79.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.